Fast-Track Review Channels in China: Breakthrough vs Conditional
Fast-Track Review Channels in China: Breakthrough vs Conditional Understanding China’s Fast-Track Review Pathways: Breakthrough vs Conditional Approval Introduction China has emerged as one of the most dynamic clinical trial markets, driven by regulatory reforms designed to accelerate patient access to innovative therapies. Among the most impactful changes introduced by the National Medical Products Administration (NMPA)…
Read More “Fast-Track Review Channels in China: Breakthrough vs Conditional” »